Prediction of Chemotherapy Response by PET-CT in Osteosarcoma: Correlation with Histologic Necrosis

Journal of Pediatric Hematology/Oncology

Volumn 33, Issue 7, 2011, Pages

  Bajpai, Jyoti ^a,c   Kumar, Rakesh ^b,c   Sreenivas, Vishnubhatla ^b,c   Chand Sharma, Mehar ^b,c   Khan, Shah Alam ^b,c   Rastogi, Shishir ^b,c   Malhotra, Arun ^b,c   Gamnagatti, Shivanand ^a,b,c   Kumar, Rajender ^b,c   Safaya, Rajni ^b,c   Bakhshi, Sameer ^a,c  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

^b Department of Nuclear Medicine ^*  (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

chemotherapy; osteosarcoma; PET CT; response

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTERMETHOD COMPARISON; MALE; METABOLISM; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOPEDIC SURGERY; OSTEOSARCOMA; PATHOLOGICAL ANATOMY; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR NECROSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NECROSIS; NEOADJUVANT THERAPY; OSTEOSARCOMA; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053350449     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Winkler K, Bieling P, Bielack S, et al. Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry. Clin Orthop. 1991;270:79-86.
2. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-790. (Pubitemid 34111386)
3. Saeter G, Hoie J, Stenwig AE, et al. Systemic relapse of patients with osteogenic sarcoma: prognostic factors for long term survival. Cancer. 1995;75:1084-1093.
4. Dutour A, Decouvelaere AV, Monteil J, et al. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model. J Nucl Med. 2009;50:1533-1540.
5. Cheon GJ, Kim MS, Lee JA, et al. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. J Nucl Med. 2009; 50:1435-1440.
6. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-214. (Pubitemid 11167383)
7. Rosen G, Capaeros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumour to preoperative chemotherapy. Cancer. 1982;49:1221-1230. (Pubitemid 12187826)
8. Bacci G , Ferrari S, Bertoni F, et al. Long term outcome for patients with nonmetastatic osteogenic sarcoma of the extremity treated at the instituto orthopedo Rezzoli according to the instituto OR/O-2 protocol: an updated report. J Clin Oncol. 2000;18:4016-4027. (Pubitemid 32038393)
9. Provisor AJ, ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteogenic sarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the childrens cancer group. JCO. 1995; 15:76-84. (Pubitemid 27020560)
10. Iagaru A, Masamed R, Chawla SP, et al. F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas. Clin Nucl Med. 2008;33:8-13.
11. Z Ye, Zhu J, Tian M, et al. Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG- PET. Ann Nucl Med. 2008; 22:475-480.
12. Evilevitch V, Weber WA, Tap WD, et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2008;14: 715-720. (Pubitemid 351231152)
13. Hankins DS, Conrad EU 3rd, Butrynski JE, et al. F-[18]- fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer. 2009;115:3519-3525.
14. Hawkins DS, Schuteze SM, Butrynski JE, et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005; 23:8828-8834. (Pubitemid 46211529)
15. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2005;103:339-344.
16. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual (ed 6). New York: Springer; 2002.
17. Picci P, Bacci G, Campanaci M, et al. Histological evaluation of necrosis in osteosarcoma induced by chemotherapy: regional mapping of viable and nonviable tumor. Cancer 1985;56:1515.
18. Nathan SS, DiResta GR, Casas-Ganem JE, et al. Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin Cancer Res 2005; 11:2389-2397. (Pubitemid 40490200)
19. Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med. 1999;40:1637-1643. (Pubitemid 29471153)
20. Nair N, Ali A, Green AA, et al. Response of osteosarcoma to chemotherapy: evaluation with F-18 FDG-PET scans. Clin Positron Imaging. 2000; 3:79-83.
21. Franzius C, Sciuk J, Brinkschmidt C, et al. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med. 2000;25:874-881.
22. Kumar A, Kumar R, Seenu V, et al. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol. 2009;19:1347-1357.
23. Hawkins DS, Rajendran JG, Conrad EU III, et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F- 18]-fluorodeoxy-D- glucose positron emission tomography. Cancer. 2002;94:3277-3284. (Pubitemid 34670512)
24. Benz MR, Allen-Auerbach MS, Eilber FC, et al. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med. 2008;49:1579-1584.
25. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumor response using 18F-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-1782.
26. Shin KH, Moon SH, Suh JS, et al. Tumor Volume Change as a Predictor of Chemotherapeutic Response in Osteosarcoma. Clin Orthop Relat Res. 2000;376: 200-208.